Want to see CV full AI Analyst Report?
CV Stock Chart & Stats
$13.23
--
Market closed
$13.23
--
Day’s Range― - ―
52-Week Range$3.43 - $15.37
Previous CloseN/A
VolumeN/A
Average Volume (3M)45.47K
Market Cap
$299.28M
Enterprise Value$307.62M
Total Cash (Recent Filing)$17.93M
Total Debt (Recent Filing)$788.00K
Price to Earnings (P/E)―
Beta-1.75
Next Earnings
Aug 13, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding49,963,585
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)197.96
Price to Sales (P/S)193.67
P/FCF Ratio-114.36
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue22.68
Enterprise Value/Gross Profit43.90
Enterprise Value/Ebitda-11.54
Forecast
1Y Price Target
$11.00Price Target Upside-16.86% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$15.80M
Bulls Say, Bears Say
Bulls Say
Revenue & Gross MarginSustained double‑digit top‑line growth alongside stable mid‑50s gross margins indicates durable product demand and unit economics in capsule endoscopy. This combination supports scalable revenue expansion and the potential for operating leverage as fixed costs are absorbed over time.
Operating ImprovementMovement to near‑breakeven at the operating level reflects improving cost discipline or higher margin mix, a structural positive. Persisting operating improvement reduces incremental funding needs, extends runway, and signals management can manage expense structure as commercialization progresses.
Clinical Expertise & GovernanceAdding a veteran gastroenterologist to the board and achieving shareholder votes/auditor ratification strengthens clinical credibility and governance. Enhanced clinical oversight and audited reporting are durable supports for regulatory, clinical trial, and commercialization execution over the medium term.
Bears Say
Cash Burn & Weak Cash FlowConsistently large negative operating and free cash flows over multiple years create a structural dependence on external financing. Persistent cash burn constrains strategic flexibility, raises dilution risk, and makes long‑term product investment contingent on securing durable funding sources.
Accumulated Losses / Equity VolatilityA history of negative equity and volatile ROE reflects accumulated losses that have eroded the capital base. Even with low reported debt, this structural weakness raises the probability of future financing, potential dilution, and limits the company's ability to fund growth without external support.
Severe Net LossesExtremely negative net margins despite revenue gains indicate the company is not yet converting sales into sustainable profits. This persistent bottom‑line weakness hampers free cash generation, constrains reinvestment capacity, and requires a credible path to profitability to alter long‑term risk dynamics.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $3.43 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $299.28M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 31 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on May 14, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.02.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Overvalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate is -0.13.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 49,963,585 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -11.575%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (-16.86% Downside)
$11.00 (-16.86% Downside)
Blogger Sentiment
Bullish
CV Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $596.9K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
126.84%
Trailing 12-Months
Asset Growth
108.43%
Trailing 12-Months
Company Description
CapsoVision, Inc.
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
CV Earnings Call
Q1 2026
0:00 / 0:00
CV Stock 12 Month Forecast
Average Price Target
$11.00
▼(-16.86% Downside)
Technical Analysis
Ownership Overview
8.51% Insiders
3.17% Mutual Funds
0.02% Other Institutional Investors
83.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---